Welcome to ALK in the United Kingdom and the Republic of Ireland.
ALK is committed to improving the quality of life for allergy sufferers by developing products that target the allergy itself, rather than just relieving its symptoms.
During the global coronavirus outbreak, our key priority is to safeguard the continued supply of our medicines to people with allergy.
We are making every effort to ensure an uninterrupted supply of our disease-modifying and potentially life-saving therapies, so patients can be confident that they will be able to continue and complete their treatment programs.
The situation is continually evolving, but currently we are not experiencing any supply constraints.
We are well prepared for situations like this and have robust inventories of allergy immunotherapy medicine.